Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Devayani Machiraju"'
Autor:
Devayani Machiraju, Jessica C. Hassel
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
The liver is the most preferential initial site of metastasis for uveal melanoma (mUM), and this preference is associated with rapid mortality in mUM patients. Despite the significant clinical benefits of Immune checkpoint inhibitors (ICIs) in metast
Externí odkaz:
https://doaj.org/article/448fd1802dba4a3a9b6e3889fd777c85
Autor:
Devayani Machiraju, Sarah Schäfer, Philip Beckhove, Jasmin Roth, Carsten Schulz, Jessica C. Hassel
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundImmune checkpoint inhibitors (ICIs) are the standard of care for metastatic cutaneous melanoma (mCM) patients, but their efficacy in young adults aged less than 40 years remains unclear.Materials and methodsWe retrospectively analyzed 303 s
Externí odkaz:
https://doaj.org/article/646175c279a64f3eabccd97e1ea8b6aa
Autor:
Jessica C. Hassel, Timo E. Schank, Heiko Smetak, Jasmin Mühlbauer, Martin Salzmann, Devayani Machiraju, Christian Menzer, Kristin Lang, Laila König, Matthias F. Haefner, Ingrid Hülsmeyer, Christian Kohler, Rainer Spang, Alexander Enk, Jürgen Debus, Philipp Beckhove
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
In patients with melanoma brain metastases (MBM), a combination of radiotherapy (RT) with immune checkpoint inhibitors (ICI) is routinely used. However, the best sequence of radio-immunotherapy (RIT) remains unclear. In an exploratory phase 2 trial,
Externí odkaz:
https://doaj.org/article/5c11e7dab9974230b5dc3d9f87c8177f
Autor:
Devayani Machiraju, Melanie Wiecken, Nina Lang, Ingrid Hülsmeyer, Jasmin Roth, Timo E. Schank, Rosa Eurich, Niels Halama, Alexander Enk, Jessica C. Hassel
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Different mechanisms lead to immune checkpoint inhibitor (ICI) resistance. Identifying clinically useful biomarkers might improve drug selection and patients’ therapy. We analyzed the soluble immune checkpoints sPD1, sPDL1, sLAG3, and sTIM3 using E
Externí odkaz:
https://doaj.org/article/e6ad7a1313874ac4a737a25d7de643ea
Publikováno v:
Life, Vol 11, Iss 12, p 1318 (2021)
The impact of age on the clinical benefit of anti-PD1 immunotherapy in advanced melanoma patients has been evolving recently. Due to a reduced immune function in elderly patients, young patients with a robust immune system are theoretically expected
Externí odkaz:
https://doaj.org/article/ca50a690d9a54ab787184d5e75d59a94
Autor:
Sophia B. Strobel, Devayani Machiraju, Ingrid Hülsmeyer, Jürgen C. Becker, Annette Paschen, Dirk Jäger, Winfried S. Wels, Michael Bachmann, Jessica C. Hassel
Publikováno v:
Life, Vol 11, Iss 4, p 269 (2021)
Tumor antigen-specific redirection of cytotoxic T cells (CTLs) or natural killer (NK) cells including chimeric antigen receptor (CAR-) and T cell receptor (TCR-) cell therapy is currently being evaluated in different tumor entities including melanoma
Externí odkaz:
https://doaj.org/article/59b068a2a4d74cc0aa93f322b8aeb1d8
Autor:
Melanie Wiecken, Jessica C. Hassel, Nina Lang, Niels Halama, Ingrid Hülsmeyer, Alexander Enk, Jasmin Roth, Rosa Eurich, Timo E Schank, Devayani Machiraju
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Different mechanisms lead to immune checkpoint inhibitor (ICI) resistance. Identifying clinically useful biomarkers might improve drug selection and patients’ therapy. We analyzed the soluble immune checkpoints sPD1, sPDL1, sLAG3, and sTIM3 using E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::070a72a1638c42a836c548f1a513ae2e
http://europepmc.org/articles/PMC8158029
http://europepmc.org/articles/PMC8158029
Autor:
Jessica C. Hassel, Dirk Jäger, Devayani Machiraju, Michael Bachmann, Winfried S. Wels, Annette Paschen, Ingrid Hülsmeyer, Jürgen C. Becker, Sophia Boyoung Strobel
Publikováno v:
Life
Volume 11
Issue 4
Life, Vol 11, Iss 269, p 269 (2021)
Volume 11
Issue 4
Life, Vol 11, Iss 269, p 269 (2021)
Tumor antigen-specific redirection of cytotoxic T cells (CTLs) or natural killer (NK) cells including chimeric antigen receptor (CAR-) and T cell receptor (TCR-) cell therapy is currently being evaluated in different tumor entities including melanoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e6c852524e476ad4c5b8006db63c425
Publikováno v:
Cancers. 14:1215
Metastatic uveal melanoma (mUM) is one of the most rapidly progressing tumors, with a bad prognosis and no standard-of-care treatment. Immune checkpoint inhibitors have revolutionized cancer therapy and improved overall survival in patients with meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49b4727b2d4475712ad3a4734227431
https://doi.org/10.3390/cancers14051215
https://doi.org/10.3390/cancers14051215
Autor:
Antje Sucker, Devayani Machiraju, Jessica C. Hassel, Christoffer Gebhardt, Iris Moll, Dirk Schadendorf, Kristina Buder-Bakhaya
Publikováno v:
Melanoma Research. 28:204-210
Interferons (IFN) have a direct growth-inhibiting effect on tumor cells through Janus kinase-dependent activation of the transcription factor signal transducer and activator of transcription (STAT1). In vitro, signaling through STAT5 has been demonst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a15d1791938811afbae333c636fdf932
https://doi.org/10.1097/cmr.0000000000000435
https://doi.org/10.1097/cmr.0000000000000435